NYSE · Health care

AIM ImmunoTech Inc. (AIM)

AIM ImmunoTech Inc. brought in $95K of revenue over the twelve months to June 30, 2026, down 21.5% from a year earlier. It posted a net loss of $14.3M. At June 30, 2026 it held $9.9M in cash against $3.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.

Price

$0.19

-6.49% on the day · September 25, 2026

52-week range $0.19 to $2.79

Market cap

$5.8M

Revenue (last 12 months)

$95K

-21.5% year on year

Net margin

-15,021.1%

What AIM ImmunoTech Inc. does

AIM ImmunoTech Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker AIM.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$88K	-$11.7M	-$14M	-$8.62	n/a
2024	$170K	-$19.8M	-$17.3M	-$30.92	-$14.9M
2023	$202K	-$31.9M	-$29M	-$59.85	n/a
2022	$141K	-$19.9M	-$19.4M	-$39.90	-$16.2M
2021	$135K	-$18.8M	-$19.1M	-$39.90	-$14M
2020	$163K	-$15.2M	-$14.4M	-$44.88	-$10.4M

Where AIM ranks in Health care

Revenue$88K

#619 of 646 in Health care · Bottom 4%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What AIM ImmunoTech Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 14, 2026
Material agreement 8-K
September 10, 2026
Material agreement 8-K
September 4, 2026
Material agreement 8-K
August 11, 2026
Investor disclosure 8-K
August 10, 2026
Quarterly results 8-K
August 7, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue rose 4% to $26K versus the same quarter last year; diluted EPS -$0.43 versus -$3.68.
August 6, 2026
Material agreement 8-K
August 5, 2026
Material agreement ended 8-K
July 16, 2026
Shareholder vote results 8-K
July 9, 2026
Employee stock plan registration S-8

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 18, 2026. Insider transactions on SEC

Insider trades

What the people running AIM ImmunoTech Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $13.5K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)

$13.5K

last 90 days

Sold

last 90 days

Net bought

62,900

$13.5K

Date	Insider	What	Shares	Price	Value	Filing
September 17, 2026	Equels Thomas KCEO & President, Director	Bought	24,000	$0.21	$5K	Form 4
September 16, 2026	Equels Thomas KCEO & President, Director	Bought	11,000	$0.21	$2.3K	Form 4
September 15, 2026	Equels Thomas KCEO & President, Director	Bought	22,000	$0.22	$4.9K	Form 4
September 14, 2026	Equels Thomas KCEO & President, Director	Bought	5,900	$0.22	$1.3K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns AIM

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Orca Capital AG13G, passive	9.9%	1,793,999	May 12, 2026

Latest filings below 5%: Mitchell P. Kopin 0% (May 27, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 126,822 shares in total, about $24.1K at the last price.

Holder	Shares	As of
Equels Thomas KCEO & President, Director	126,822	September 17, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about AIM

What does AIM ImmunoTech Inc. do?

AIM ImmunoTech Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker AIM.

Is AIM ImmunoTech Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $14.3M on revenue of $95K.

How much revenue does AIM ImmunoTech Inc. make?

Over the twelve months to June 30, 2026 AIM ImmunoTech Inc. reported revenue of $95K. That is 21.5% less than a year earlier.

When did AIM ImmunoTech Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 18, 2026.

Similar companies

AMGN

Amgen Inc

GILD

Gilead Sciences, Inc.

Neurocrine Biosciences Inc

EXEL

Exelixis, Inc.

Compare AIM with

Compare AIM with any company

Follow AIM

Get an email when AIM ImmunoTech Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow AIM: get an email when it files

Where the numbers come from

Financial figures are the values AIM ImmunoTech Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.